{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:26Z","timestamp":1793054666974,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13560-9","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T17:34:42Z","timestamp":1765215282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of GLP-1 receptor agonists on cranial nerve palsies in type 2 diabetes: a retrospective cohort study"],"prefix":"10.1007","volume":"273","author":[{"given":"Ronak","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Al-Bana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimezie","family":"Amaefuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banuja","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-544X","authenticated-orcid":false,"given":"Rawan","family":"Elkomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Fahad","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Beyene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekdem","family":"Bisrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"5","key":"13560_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.2337\/dc08-1826","volume":"32","author":"A Basu","year":"2009","unstructured":"Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA (2009) Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 32(5):866\u2013872. https:\/\/doi.org\/10.2337\/dc08-1826","journal-title":"Diabetes Care"},{"issue":"1","key":"13560_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MA Khan","year":"2020","unstructured":"Khan MA, Hashim MJ, King J, Govender RD, Mustafa H, Al Kaabi J (2020) Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107\u2013111. https:\/\/doi.org\/10.2991\/jegh.k.191028.001","journal-title":"J Epidemiol Glob Health"},{"key":"13560_CR3","unstructured":"Collins L, Costello RA. (2024) Glucagon-like peptide-1 receptor agonists. PubMed. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"issue":"24","key":"13560_CR4","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/circulationaha.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 146(24):1882\u20131894. https:\/\/doi.org\/10.1161\/circulationaha.122.059595","journal-title":"Circulation"},{"key":"13560_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.72080","author":"JO Olukorode","year":"2024","unstructured":"Olukorode JO, Orimoloye DA, Nwachukwu NO et al (2024) Recent advances and therapeutic benefits of glucagon-like peptide-1 (GLP-1) agonists in the management of type 2 diabetes and associated metabolic disorders. Cureus. https:\/\/doi.org\/10.7759\/cureus.72080","journal-title":"Cureus"},{"issue":"8415","key":"13560_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D et al (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384(8415):e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"issue":"1","key":"13560_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11\u201322. https:\/\/doi.org\/10.1056\/nejmoa1411892","journal-title":"N Engl J Med"},{"issue":"3-4","key":"13560_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/rds.2014.11.202","volume":"11","author":"TD Filippatos","year":"2015","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS (2015) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 11(3\u20134):202\u2013230. https:\/\/doi.org\/10.1900\/rds.2014.11.202","journal-title":"Rev Diabet Stud"},{"issue":"1","key":"13560_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2014.0188","volume":"17","author":"F Sun","year":"2015","unstructured":"Sun F, Chai S, Yu K et al (2015) Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther 17(1):35\u201342. https:\/\/doi.org\/10.1089\/dia.2014.0188","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"13560_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/dom.12297","volume":"16","author":"CB Giorda","year":"2014","unstructured":"Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R (2014) A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab 16(11):1041\u20131047. https:\/\/doi.org\/10.1111\/dom.12297","journal-title":"Diabetes Obes Metab"},{"key":"13560_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"issue":"2","key":"13560_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/ijms25021087","volume":"25","author":"N Sodum","year":"2024","unstructured":"Sodum N, Mattila O, Sharma R et al (2024) Nutrient Combinations Sensed by L-Cell Receptors Potentiate GLP-1 Secretion. Int J Mol Sci 25(2):1087","journal-title":"Int J Mol Sci"},{"key":"13560_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol"},{"issue":"2","key":"13560_CR14","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.2337\/db06-s020","volume":"55","author":"GE Lim","year":"2006","unstructured":"Lim GE, Brubaker PL (2006) Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes 55(2):S70\u2013S77. https:\/\/doi.org\/10.2337\/db06-s020","journal-title":"Diabetes"},{"issue":"1","key":"13560_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):1\u201329. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"13560_CR16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/ijo.2012.208","volume":"37","author":"JJ Holst","year":"2013","unstructured":"Holst JJ (2013) Incretin hormones and the satiation signal. Int J Obes 37(9):1161\u20131168. https:\/\/doi.org\/10.1038\/ijo.2012.208","journal-title":"Int J Obes"},{"issue":"7","key":"13560_CR17","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1210\/en.2009-0220","volume":"150","author":"DL Williams","year":"2009","unstructured":"Williams DL (2009) Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 150(7):2997\u20133001. https:\/\/doi.org\/10.1210\/en.2009-0220","journal-title":"Endocrinology"},{"issue":"1","key":"13560_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4239\/wjd.v6.i1.92","volume":"15","author":"SM Chung","year":"2015","unstructured":"Chung SM (2015) Ocular complications of diabetes mellitus. World J Diabetes 15(1):92\u2013108. https:\/\/doi.org\/10.4239\/wjd.v6.i1.92","journal-title":"World J Diabetes"},{"issue":"9","key":"13560_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2337\/dc08-0342.PMID:18753669;PMCID:PMC2518369","volume":"31","author":"VS Jeganathan","year":"2008","unstructured":"Jeganathan VS, Wang JJ, Wong TY (2008) Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care 31(9):1905\u20131912. https:\/\/doi.org\/10.2337\/dc08-0342.PMID:18753669;PMCID:PMC2518369","journal-title":"Diabetes Care"},{"issue":"1","key":"13560_CR20","doi-asserted-by":"publisher","first-page":"T31","DOI":"10.1530\/joe-13-0221","volume":"221","author":"C H\u00f6lscher","year":"2013","unstructured":"H\u00f6lscher C (2013) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 221(1):T31\u2013T41. https:\/\/doi.org\/10.1530\/joe-13-0221","journal-title":"J Endocrinol"},{"issue":"3","key":"13560_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1476-5381.2009.00486.x","volume":"159","author":"A Harkavyi","year":"2010","unstructured":"Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159(3):495\u2013501. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00486.x","journal-title":"Br J Pharmacol"},{"key":"13560_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997578","author":"J Chen","year":"2022","unstructured":"Chen J, Mei A, Wei Y et al (2022) GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.997578","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13560-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13560-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13560-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:57:16Z","timestamp":1773665836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13560-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13560"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13560-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests (financial or non-financial) relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This retrospective analysis used only de-identified data from the TriNetX Global Collaborative Network. Because no identifiable private information was accessed, this work did not constitute human subjects research and institutional review board approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentations"}},{"value":"Generative artificial intelligence (OpenAI ChatGPT) was used only for language editing and formatting. No AI tool was used to generate data, perform analyses, or draw scientific conclusions. All content was reviewed and approved by the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative AI"}}],"article-number":"16"}}